Abstract：
Overactivation of mineralocorticoid receptors occurs in cardiorenal diseases. Many patients with type 2 diabetes often progress to chronic kidney disease (CKD) and require dialysis. Finerenone is the first oral non-steroidal mineralocorticoid receptor (MR) antagonist used in patients with diabetic kidney disease and heart failure. Finerenone (also known as Kerendia) is more potent than spironolactone in reducing the progression of CKD and exerts its effect equally on the heart and kidneys, improving cardiovascular outcomes. Research demonstrates that finerenone improves proteinuria and glomerular filtration rate (GFR) if taken alone or in combination with sodium-glucose transporter 2 inhibitors (SGLT2i). Finerenone has been found to decrease mortality in patients with diabetic renal disease and improve quality of life. Its side effects, unlike those of spironolactone, do not include gynecomastia. However, it can result in hyperkalemia, which needs to be monitored. In this narrative review, we aim to investigate the mechanisms of action of finerenone and its implications in patients with type 2 diabetes.
摘要：
盐皮质激素受体的过度激活发生在心肾疾病中。许多2型糖尿病患者通常进展为慢性肾脏疾病（CKD）并需要透析。Finerenone是第一个口服非甾体盐皮质激素受体（MR）拮抗剂，用于糖尿病肾病和心力衰竭患者。Finerenone（也称为Kerendia）在减少CKD的进展方面比螺内酯更有效，并且对心脏和肾脏具有同等作用。改善心血管结局。研究表明，如果单独服用或与钠-葡萄糖转运蛋白2抑制剂（SGLT2i）联合服用，fineterone可以改善蛋白尿和肾小球滤过率（GFR）。已发现Finerenone可降低糖尿病肾病患者的死亡率并改善生活质量。它的副作用，不像螺内酯,不包括男性乳房发育症。然而,会导致高钾血症,这需要被监控。在这篇叙述性评论中，我们的目的是探讨2型糖尿病患者中芬酮的作用机制及其意义.
